Sep 18, 2026•3 min read
FDA approves NEXLIZET (bempedoic acid and ezetimibe) – NDA211617
The FDA approved NEXLIZET, an oral tablet combining bempedoic acid 180 mg and ezetimibe 10 mg, under NDA 211617. The approval and subsequent labeling updates are documented.